Satralizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Satralizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
25
Registered trials
36
Result records
31
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Satralizumab can convert its Monoclonal antibody profile and IL-6R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Satralizumab (query alias: satralizumab) |
|---|---|
| Modality / target | Monoclonal antibody; IL-6R; Interleukin-6 receptor antagonists |
| Highest global status | Approved |
| Originator | Roche Registration GmbH |
| Active developers | F. Hoffmann-La Roche Ltd., Roche China Holding Ltd., Hoffmann-La Roche, Inc. |
The MCP disease footprint includes AQP4-IgG positive Neuromyelitis optica spectrum disorder, Neuromyelitis Optica, Graves Ophthalmopathy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07010302 | Phase 4 | Not yet recruiting | 540 | Time to adjudicated safety or tolerability failure |
| NCT06450639 | Phase 2 | Terminated | 30 | Group 2: Change From Baseline to Week 24 in Lumbar Spine (LS) Bone Mineral Density (BMD) Z-score Measured by Dual-energy X-ray Absorptiometry (DEXA) |
| NCT06885957 | Not Applicable | Recruiting | 200 | Time to first relapse |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A real-world study of the effectiveness and safety of ravulizumab in AQP4+ NMOSD patients with suboptimal response to satralizumab in Japan - interim analysis
Not Applicable; n=11; evaluation: Positive. Reported fields: No relapse(within 12 months) = 10 Pts
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study
Phase 3; n=166; evaluation: Positive. Reported fields: AE = 299.4 per 100 person-years
Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: Infection rates = 113.0 IR/100 PY ( 98.6 - 129.0); Infection rates = 91.7 IR/100 PY ( 85.5 - 98.3)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Satralizumab addresses AQP4-IgG positive Neuromyelitis optica spectrum disorder, Neuromyelitis Optica, Graves Ophthalmopathy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 31 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IL-6R records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-08-22 | Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab | Approved | Financial terms not disclosed |
| 2025-04-02 | 百奥泰从Biogen重新获得商业化 BAT1806的权利 | Phase 3 | US$30.0M upfront |
| 2025-04-01 | Orsini Selected as the Exclusive Specialty Pharmacy for Cell Therapy ENCELTO™ | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Treatment and prevention of muscular dystrophy and its related diseases or disorders with satralizumab”. The milestone feed surfaced a patent-application signal described as “Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
